America’s first clinical trial using CRISPR for cancer was launched at the University of Pennsylvania in 2019, and it’s still ongoing. In that trial, researchers are testing an immunotherapy treatment using a patient’s genetically modified immune cells.The immunotherapy treatment uses modifications to T cells—the immune cells that may be able to detect and kill cancer cells. CRISPR was used to remove three genes that may interfere with or limit the cells’ ability to kill cancer.
top of page
bottom of page